Anagram Therapeutics, Inc.

Quick facts

Phase 2 pipeline

• ANG003 Dose A
  ANG003 Dose A is an investigational RNA-targeting therapy.
• ANG003 Dose B
  ANG003 Dose B is an investigational RNA-targeting therapy.

Phase 1 pipeline

• ANG003

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Anagram Therapeutics, Inc. portfolio CI brief
• Anagram Therapeutics, Inc. pipeline updates RSS